The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study
We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who began to...
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2008, Vol.18 (6), p.609-614 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 614 |
|---|---|
| container_issue | 6 |
| container_start_page | 609 |
| container_title | Modern rheumatology |
| container_volume | 18 |
| creator | Suda, Akiko Nagaoka, Shouhei Ohono, Shigeru Ideguchi, Haruko Soga, Takayoshi Ishigatsubo, Yoshiaki |
| description | We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January 1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients), 44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50, 70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3% achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ) (15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line DMARD was demonstrated. |
| doi_str_mv | 10.1007/s10165-008-0103-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69869330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69869330</sourcerecordid><originalsourceid>FETCH-LOGICAL-p279t-af1544de82777e7631c4312ec196bb54187bf4b28aa5b471562b15720bb8a4a83</originalsourceid><addsrcrecordid>eNpdkU1rHDEMhk1oSNKkP6CXYnrobRp_ju3eQj7aQkIgpGdjezRdh53x1vYU9p4fHi-bUOhJQnr0IulF6CMlXykh6rxQQnvZEaI7Qgnv1AE6oYKbTvXEvHvLpZHH6H0pT4RwabQ5QsdU95ppbU7Q8-MKMIxjDC5ssZsHXNwIdYvTiP0S4nrtpjgDdgU7XCCkeejWu8LV3cXDFY4zrk2gZnB1grnuxvIKlsnVFAfscl3lWGP51qYz1JzKBkKNfwGHtEq54lKXYXuGDke3LvDhNZ6iXzfXj5c_utv77z8vL267DVOmdm6kUogBNFNKgeo5DYJTBoGa3nspqFZ-FJ5p56QXisqeeSoVI95rJ5zmp-jLXneT058FSrVTLAHajTOkpdje6N5wThr4-T_wKS15brtZxpkS7a-qQZ9eocVPMNhNjpPLW_v23AawPVBaa_4N-Z8KJXbnoN07aJuDduegVfwFzeGMHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232744397</pqid></control><display><type>article</type><title>The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Suda, Akiko ; Nagaoka, Shouhei ; Ohono, Shigeru ; Ideguchi, Haruko ; Soga, Takayoshi ; Ishigatsubo, Yoshiaki</creator><creatorcontrib>Suda, Akiko ; Nagaoka, Shouhei ; Ohono, Shigeru ; Ideguchi, Haruko ; Soga, Takayoshi ; Ishigatsubo, Yoshiaki</creatorcontrib><description>We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January 1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients), 44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50, 70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3% achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ) (15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line DMARD was demonstrated.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1007/s10165-008-0103-7</identifier><identifier>PMID: 18682889</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - physiopathology ; Cohort Studies ; Comparative studies ; Cysteine - analogs & derivatives ; Cysteine - therapeutic use ; Drug therapy ; Female ; Health Status ; Humans ; Joints - drug effects ; Joints - physiopathology ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article ; Orthopedics ; Remission Induction ; Retrospective Studies ; Rheumatoid arthritis ; Rheumatology ; Severity of Illness Index ; Side effects ; Treatment Outcome</subject><ispartof>Modern rheumatology, 2008, Vol.18 (6), p.609-614</ispartof><rights>Japan College of Rheumatology 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-p279t-af1544de82777e7631c4312ec196bb54187bf4b28aa5b471562b15720bb8a4a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18682889$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suda, Akiko</creatorcontrib><creatorcontrib>Nagaoka, Shouhei</creatorcontrib><creatorcontrib>Ohono, Shigeru</creatorcontrib><creatorcontrib>Ideguchi, Haruko</creatorcontrib><creatorcontrib>Soga, Takayoshi</creatorcontrib><creatorcontrib>Ishigatsubo, Yoshiaki</creatorcontrib><title>The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><addtitle>Mod Rheumatol</addtitle><description>We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January 1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients), 44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50, 70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3% achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ) (15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line DMARD was demonstrated.</description><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Cohort Studies</subject><subject>Comparative studies</subject><subject>Cysteine - analogs & derivatives</subject><subject>Cysteine - therapeutic use</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health Status</subject><subject>Humans</subject><subject>Joints - drug effects</subject><subject>Joints - physiopathology</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Severity of Illness Index</subject><subject>Side effects</subject><subject>Treatment Outcome</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1rHDEMhk1oSNKkP6CXYnrobRp_ju3eQj7aQkIgpGdjezRdh53x1vYU9p4fHi-bUOhJQnr0IulF6CMlXykh6rxQQnvZEaI7Qgnv1AE6oYKbTvXEvHvLpZHH6H0pT4RwabQ5QsdU95ppbU7Q8-MKMIxjDC5ssZsHXNwIdYvTiP0S4nrtpjgDdgU7XCCkeejWu8LV3cXDFY4zrk2gZnB1grnuxvIKlsnVFAfscl3lWGP51qYz1JzKBkKNfwGHtEq54lKXYXuGDke3LvDhNZ6iXzfXj5c_utv77z8vL267DVOmdm6kUogBNFNKgeo5DYJTBoGa3nspqFZ-FJ5p56QXisqeeSoVI95rJ5zmp-jLXneT058FSrVTLAHajTOkpdje6N5wThr4-T_wKS15brtZxpkS7a-qQZ9eocVPMNhNjpPLW_v23AawPVBaa_4N-Z8KJXbnoN07aJuDduegVfwFzeGMHA</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Suda, Akiko</creator><creator>Nagaoka, Shouhei</creator><creator>Ohono, Shigeru</creator><creator>Ideguchi, Haruko</creator><creator>Soga, Takayoshi</creator><creator>Ishigatsubo, Yoshiaki</creator><general>Springer Japan</general><general>Informa Healthcare</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>2008</creationdate><title>The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study</title><author>Suda, Akiko ; Nagaoka, Shouhei ; Ohono, Shigeru ; Ideguchi, Haruko ; Soga, Takayoshi ; Ishigatsubo, Yoshiaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p279t-af1544de82777e7631c4312ec196bb54187bf4b28aa5b471562b15720bb8a4a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Cohort Studies</topic><topic>Comparative studies</topic><topic>Cysteine - analogs & derivatives</topic><topic>Cysteine - therapeutic use</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health Status</topic><topic>Humans</topic><topic>Joints - drug effects</topic><topic>Joints - physiopathology</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Severity of Illness Index</topic><topic>Side effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suda, Akiko</creatorcontrib><creatorcontrib>Nagaoka, Shouhei</creatorcontrib><creatorcontrib>Ohono, Shigeru</creatorcontrib><creatorcontrib>Ideguchi, Haruko</creatorcontrib><creatorcontrib>Soga, Takayoshi</creatorcontrib><creatorcontrib>Ishigatsubo, Yoshiaki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suda, Akiko</au><au>Nagaoka, Shouhei</au><au>Ohono, Shigeru</au><au>Ideguchi, Haruko</au><au>Soga, Takayoshi</au><au>Ishigatsubo, Yoshiaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study</atitle><jtitle>Modern rheumatology</jtitle><stitle>Mod Rheumatol</stitle><addtitle>Mod Rheumatol</addtitle><date>2008</date><risdate>2008</risdate><volume>18</volume><issue>6</issue><spage>609</spage><epage>614</epage><pages>609-614</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January 1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients), 44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50, 70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3% achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ) (15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line DMARD was demonstrated.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>18682889</pmid><doi>10.1007/s10165-008-0103-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2008, Vol.18 (6), p.609-614 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69869330 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - physiopathology Cohort Studies Comparative studies Cysteine - analogs & derivatives Cysteine - therapeutic use Drug therapy Female Health Status Humans Joints - drug effects Joints - physiopathology Male Medicine Medicine & Public Health Middle Aged Original Article Orthopedics Remission Induction Retrospective Studies Rheumatoid arthritis Rheumatology Severity of Illness Index Side effects Treatment Outcome |
| title | The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A10%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20efficacy%20and%20safety%20of%20bucillamine%20as%20a%20second-line%20DMARD%20in%20the%20treatment%20of%20rheumatoid%20arthritis:%20a%20retrospective%20cohort%20study&rft.jtitle=Modern%20rheumatology&rft.au=Suda,%20Akiko&rft.date=2008&rft.volume=18&rft.issue=6&rft.spage=609&rft.epage=614&rft.pages=609-614&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1007/s10165-008-0103-7&rft_dat=%3Cproquest_pubme%3E69869330%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232744397&rft_id=info:pmid/18682889&rfr_iscdi=true |